Alumis vs Praxis Precision Medicines
ALMS and PRAX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALMS and PRAX compare
Praxis Precision Medicines is the larger company, worth 13 times as much as Alumis ($9.2B against $725M).
Praxis Precision Medicines scores higher on the StockData Score (7 against 6 for Alumis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALMS | PRAX |
|---|---|---|
| Size and price | ||
| Market cap | $725M | $9.2B |
| Share price | $5.60 | $328.13 |
| Change, 1 year | 6.9% | 78.7% |
| Change, 5 years | – | 17.2% |
| Beta (5Y) | −1.12 | 1.65 |
| Employees | 224 | 168 |
| StockData Score | ||
| Total score | 6 | 7 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 100× | – |
| P/B | 1.9× (better) | 7.3× |
| FCF yield | −44.3% | −3.5% (better) |
| Profitability | ||
| Operating margin | −6117% | – |
| Net margin | −5845% | – |
| FCF margin | −4433% | – |
| Return on equity | −111% | −44.8% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 5.57 | 14.53 (better) |
| Altman Z-score | −1.67 | 102.83 (better) |
| Piotroski F-score | 2 | 3 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 91.3% | 121% |
| Held by insiders | 30.5% | 0.72% |
| Insider net buying, 12 months | $44.7M (better) | −$3.6M |
| Short interest, % of float | 12.3% | 15.2% |
Go deeper
- ALMS stock overview
- ALMS income statement
- ALMS valuation and score
- PRAX stock overview
- PRAX income statement
- PRAX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.